新型非典型抗精神病药布瑞哌唑的研究现状OA

Brexpiprazole,a novel atypical antipsychotic drug,has therapeutic effects in the treatment and prevention of relapse of schizophrenia.It exerts its efficacy through partial agonism of dopamine D2 receptor and 5-hydroxytryptamine receptor 1A(5-HT1A),as well as antagonism of 5-HT2A receptor.In terms of pharmacokinetics,it features high oral bioavailability,a long half-life,and minimal influence of food on its absorption.Multiple clinical trials have confirmed its effectiveness in the acute treatment(2-4 mg every day)and maintenance treatment(1-4mg every day)of schizophrenia.Regarding safety,common adverse reactions include akathisia and weight gain,with a relatively low risk of metabolic abnormalities.No systematic review of brexpiprazole has been published in China.This article conducts a systematic search for the first time and reviews it from aspects such as its mechanism of action,pharmacokinetic characteristics,clinical efficacy,and safety,providing a reference for rational clinical use.